

SEE ME
HEAR ME



RARE DISEASE DAY.ORG
#RARE DISEASE DAY

Strength In Numbers: Facts and figures about ANCA-associated vasculitis (AAV)

AAV is a rare, severe condition affecting small blood vessels...¹⁻⁴

3 types of AAV:³

GPA
MPA
EGPA



1 in 10,000 people
affected by AAV
in Europe^{5,6}



60%
MALE^{5,7}



40%
FEMALE^{5,7}

Average age of
diagnosis: **57 years**⁸

...impacting a range of areas in your body, making diagnosis difficult.^{8,9}




9 different organs
or body parts that
can be affected¹⁰



6 month delay in
diagnosis is experienced
by 1/3rd of patients⁹

Serious health issues are caused by disease and treatment...¹¹⁻¹⁴



7x higher risk
of infection¹¹



65% increased
cardiovascular risk¹³



8x higher risk
of osteoporosis¹²



26% of patients have
severe kidney issues
after 3 years¹⁴

...and AAV has a big impact on quality of life...^{15,16}



20% of working age AAV
patients were unemployed
due to their condition¹⁶



50% of AAV patients thought
their careers were hindered
due to their condition¹⁶

...but support is available for anyone affected by AAV

7 patient
association
groups across
Europe



#StrengthInNumbers

ANCA, anti-neutrophil cytoplasmic antibody; EGPA, eosinophilic granulomatosis with polyangiitis; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis.

References

1. Al-Hussain T, et al. *Adv Anat Pathol* 2017;24(4):226–34. 2. Yates M, et al. *Ann Rheum Dis* 2016;75(9):1583–94. 3. Jennette JC, et al. *Arthritis Rheum* 2013;65(1):1–11. 4. Wallace ZS and Miloslavsky EM. *BMJ* 2020;368:m421. 5. Watts RA, et al. *Nephrol Dial Transplant* 2015;30(Suppl 1):i14–22. 6. Omerod AS, Cook MC. *Intern Med J* 2008;38(11):816–23. 7. Watts RA, et al. *Arthritis Rheum* 2000;43(2):414–9. 8. Rutherford PA, et al. *J Am Soc Nephrol* 2018;29:839(Abstract SA-PO403). 9. Yates M, Watts R. *Clin Med (Lond)* 2017;17(1):60–4. 10. Pagnoux C. *Eur J Rheumatol* 2016;3(3):122–33. 11. Sarica SH, et al. *Rheumatology (Oxford)* 2020;59(10):3014–22. 12. Sarica SH, et al. *Arthritis Rheumatol* 2020;15. doi: 10.1002/art.41557. 13. Houben E, et al. *Rheumatology (Oxford)* 2018;57(3):555–62. 14. Lionaki S, et al. *Kidney Int* 2009;76(6):644–51. 15. Basu N, et al. *Ann Rheum Dis* 2014;73(1):207–11. 16. Benarous L, et al. *Clin Exp Rheumatol* 2017;35 Suppl 103(1):40–6.



RARE IS **MANY** RARE IS **STRONG** RARE IS **PROUD**